<DOC>
	<DOC>NCT01649570</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of NovoRapidÂ® (insulin aspart) as meal time insulin in subjects with type 2 diabetes treated on a basal-bolus regimen with Neutral Protamine Hagedorn (NPH) human insulin.</brief_summary>
	<brief_title>Safety and Efficacy of Insulin Aspart in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Treated with insulin for at least 12 months and currently on a basalbolus regimen for at least 12 weeks HbA1c below or equal to 11.0% BMI (body mass index) below 30 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>